Introduction
============

Breast cancer (BC) is the leading cause of cancer deaths among females worldwide, with an estimated ⩾500,000 deaths occurring in 2012.[@b1-ott-11-5485] As the incidence of BC is increasing rapidly,[@b2-ott-11-5485] understanding the biological mechanisms involved and exploring novel targets are urgently needed.

EF-hand proteins are a large number of Ca2^+^-binding proteins.[@b3-ott-11-5485],[@b4-ott-11-5485] The EF-hand is a helix--loop--helix calcium-binding motif. They are involved in various biological processes, including inflammation, exocytosis, motility, apoptosis, tumor progression, and so on.[@b3-ott-11-5485]

Allograft inflammatory factor 1 like (AIF1L) is a protein with EF-hand motifs lacking bound Ca[@b2-ott-11-5485]^+^.[@b5-ott-11-5485] AIF1L consists of 150 amino acids, and the sequence identity to AIF1 is 60%. AIF1 protein is majorly expressed in the immune cells and participates in the inflammatory response and regulation.[@b6-ott-11-5485] AIF1 can activate the monocyte/macrophage, microglia, and lymphocyte immune cells, promote the expression of inflammatory mediators such as cytokines, chemokines, nitric oxide synthase, and boost immune cell proliferation and migration.[@b7-ott-11-5485]--[@b9-ott-11-5485] However, AIF1L is majorly expressed in the epithelial cells, such as renal glomerulus and renal tubules, endometrial gland, mammary ductal epithelial cells, glandular epithelium of epididymis, and vascular endothelial cells of spleen.[@b10-ott-11-5485],[@b11-ott-11-5485] Although AIF1 and AIF1L have remarkable sequence homology and structural similarity, they show a distinct pattern of tissue specific expression, so we speculated they have different biological functions.

AIF1L co-localizes with and crosslinks filamentous actin (F-actin) with subcortical filaments and localizes to membrane ruffle-like cellular projections and adhesion structures in a Shigella invasion model.[@b5-ott-11-5485] AIF1L deficiency, which was functionally analyzed by siRNA silencing, was shown to result in significant loss and rearrangement of F-actin stress fibers, as shown by phalloidin staining, and led to cytoskeletal injury in immortalized human podocytes.[@b12-ott-11-5485] So far, the potential roles of AIF1L in carcinogenesis have not been well characterized.

We studied AIF1L expression levels in BC, the effects of AIF1L on migration and invasion of BC cells, and characterized an AIF1L-related signaling pathway that influences cytoskeletal modifications.

Patients and methods
====================

Cell culture and engineering
----------------------------

The MDA-MB-231 BC cell line was purchased from American Type Culture Collection. Cells were cultured in L15 medium (Hyclone) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, MA USA). Adenoviruses purchased from Hanbio Biotechnology Co., Ltd. (Shanghai, People's Republic of China) were used to overexpress human AIF1L in MDA-MB-231 cells via transient transfection.

Microarray and immunohistochemistry
-----------------------------------

A total of 287 tissue samples from primary BC patients who underwent curative resection were collected at the First Hospital of China Medical University between December 2003 and April 2007. Tissue specimens were initially paraffin embedded and processed for routine histological evaluation. Written informed consent was obtained from each patient. Clinicopathologic data, including age, gender, World Health Organization histological type, and TNM stage, as well as estrogen receptor (ER), progesterone receptor (PR), Ki67, and human epidermal growth factor receptor 2 (HER2) expression, were collected. A total of 259 BC patients with at least a 5-year follow-up were included in prognosis analysis. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of China Medical University. All samples were evaluated by two experienced pathologists to confirm diagnosis. AIF1L expression levels were detected using a two-step immunohistochemical method (Beijing Zhongshan Golden Bridge Biotechnology Company, Beijing, People's Republic of China). Rabbit polyclonal antibodies against human AIF1L were purchased from Abcam (Shanghai, People's Republic of China). Tissue microarray slides were deparaffinized in xylene and hydrated with graded alcohol before incubation with 3% H~2~O~2~ and heat-induced antigen retrieval. Slides were incubated with primary antibodies overnight at 4°C and stained using a two-step detection system; counterstaining was performed with hematoxylin. All procedures were carried out according to the manufacturers' instructions. For negative controls, sections were treated with 0.01 mol/L PBS instead of primary antibodies.

Cells expressing AIF1L proteins had visible brown granules in the cytoplasm and membrane. Immunostaining intensities were evaluated by two independent pathologists in a blinded manner. The scoring system was based on the intensity and extent of staining. Expression levels were classified as low and high, as previously described.[@b13-ott-11-5485]

Biological informatics analysis for AIF1L expression and methylation
--------------------------------------------------------------------

The Cancer Genome Atlas (TCGA) RNA-sequencing database (level 3 data) included 1,100 BC samples and 112 normal controls. To identify an association between AIF1L methylation and expression, we also downloaded HumanMethylation450 data (level 3 data) for breast tumor tissues and adjacent non-tumor tissues from TCGA. The association between AIF1L mRNA expression and DNA methylation was determined by calculating the Spearman correlation coefficient. The total number of matched samples was 868. Beta-value statistics were used to measure methylation levels.[@b14-ott-11-5485] AIF1L protein expression in BC was confirmed according to The Human Protein Atlas.[@b50-ott-11-5485]

Cancer Cell Line Encyclopedia (CCLE) data analysis
--------------------------------------------------

The CCLE project is an effort to conduct detailed genetic characterization of a large panel of human cancer cell lines. CCLE provides public access analysis and visualization of DNA copy number, mRNA expression, mutation data, and more for \~1,000 cancer cell lines,[@b15-ott-11-5485],[@b16-ott-11-5485] including 52 BC cells that were analyzed in the present study. We withdrew AIF1L co-expression genes from the CCLE database with R language, then used DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases, MD, USA, National Institutes of Health \[NIH\]) for gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses (<https://david.abcc.ncifcrf.gov/>).[@b17-ott-11-5485],[@b18-ott-11-5485] Data from the BC cell lines were also evaluated using gene set enrichment analysis (GSEA) and GSEA2-2.2.3 software. AIF1L expression levels were dichotomized into two groups to annotate phenotype with msigdb.v5.2.symbols gene sets.[@b19-ott-11-5485],[@b20-ott-11-5485] All other parameters were set to default values.[@b21-ott-11-5485],[@b22-ott-11-5485]

Transwell migration and invasion assays
---------------------------------------

Migration and invasion assays were performed as previously described.[@b23-ott-11-5485] For the invasion assays, 50 µL Matrigel (Corning, NY, USA) was added to the well inserts and incubated overnight. Cells (5×10^4^) were suspended in serum-free culture media and seeded into Transwell inserts. Plates on the bottom received complete media and were incubated at 37°C for 24 hours. Unmigrated cells were removed using cotton swabs. Cells were fixed with 4% paraformaldehyde and stained with a 1% crystal violet solution (Sigma-Aldrich St. Louis, MO, USA). For each plate, five random fields were counted at 10× magnification. Images were processed with ImageJ software to count the number of cells in the migration and invasion assay.

Protein extraction and immunoblots
----------------------------------

Cells were solubilized in radioimmunoprecipitation assay lysis buffer with protease inhibitors. Equal amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% nonfat milk for 2 hours and incubated overnight at 4°C with primary antibodies. Proteins were detected using an enhanced chemiluminescence kit and photographed using the ChemiDoc MP System (Bio-Rad Laboratories Inc., Hercules, CA, USA). Rabbit monoclonal antibodies against human FAK and RHOA were purchased from Abcam.

Cell spreading assays
---------------------

A cell spreading assay was performed as previously described.[@b24-ott-11-5485] MDA-MB-231 controls and AIF1L-overexpressing cells were resuspended in serum-free medium. A total of 5×10^4^ cells were added to Matrigel-coated glass coverslips. Sixty minutes after plating, cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature. After washing with PBS, 0.1% Triton X-100 (in PBS) was added for 10 minutes at room temperature. Cells were blocked with 10% normal goat serum for 10 minutes at room temperature. Cells were incubated with 0.5 µM tetramethylrhodamine-phalloidin (Sigma-Aldrich) for 1 hour at room temperature and counterstained with 4′,6-diamidino-2-phenylindole to visualize nuclei. Coverslips were imaged using epifluorescence microscopy (Nikon Corporation, Tokyo Japan). Images were processed with ImageJ software to measure the areas of the cell and nucleus. Circularity and aspect ratio were used to measure cell shape as previously described.[@b25-ott-11-5485],[@b26-ott-11-5485] Both cell circularity and aspect ratio were used to measure the roundness of a cell. Over 50 cells were quantified per sample. The experiment was performed in three technical replicates.

Statistical analysis
--------------------

Statistical analysis was performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) or R language. Continuous data are shown as the mean ± SD or standard error of mean for normally distributed data. Chi-squared test or Fisher's exact test was used to compare different groups. Log-rank testing was used to assess the associations between disease-free survival and disease covariates to identify prognostic factors. Two sided *P*⩽0.05 was considered statistically significant.

Results
=======

Downregulation of AIF1L expression in BC
----------------------------------------

In this cohort, positive rates of AIF1L protein expression in BC (28.6%, 82/287) were significantly lower than in tumor-adjacent tissues (58.3%, 28/48; *P*=0.007; [Figure 1A and B](#f1-ott-11-5485){ref-type="fig"}). AIF1L mRNA expression was also significantly decreased in BC compared with controls in TCGA ([Figure 1E](#f1-ott-11-5485){ref-type="fig"}). Methylation of gene CpG island promoters is a generally accepted mechanism for silencing expression. Strong associations between methylation patterns and expression have been reported.[@b27-ott-11-5485] HumanMethylation450 BeadChip (450 K) is based on the Illumina Technology and contains 482,421 probes, targeting 99% of genes and 96% of CpG island regions.[@b28-ott-11-5485] Spearman correlation coefficients were calculated, which showed a negative correlation between the expression and methylation of *AIF1L* genes ([Figure 1G](#f1-ott-11-5485){ref-type="fig"}). Notably, AIF1L genes were hypermethylated in tumor samples compared to normal controls ([Figure 1F](#f1-ott-11-5485){ref-type="fig"}). Using data from Protein Atlas, AIF1L protein staining against HPA020522 and HPA056852 antibodies (rabbit polyclonal antibody; Sigma-Aldrich) was visible in both the cytoplasm and membranes. Normal breast glandular cells showed higher staining intensity for HPA020522 and medium staining intensity for HPA056852. Results of staining BC cells are as follows: medium (2/12), low (2/12), and not detected (8/12) for HPA020522 and medium (4/12), low (5/12), and not detected (3/12) for HPA056852.

Correlation between AIF1L levels and clinicopathologic factors
--------------------------------------------------------------

Positive rates of AIF1L expression in HER2^+^ were significantly higher than HER2^−^ (*P*=0.038). AIF1L expression was lower in triple-negative breast cancer (TNBC) compared with non-TNBC. No significant differences in AIF1L levels were detected in relation to age, T&N stage subtype, ER and PR status, and Ki67 status ([Table 1](#t1-ott-11-5485){ref-type="table"}).

Low expression of AIF1L correlates with shorter disease-free survival in BC patients
------------------------------------------------------------------------------------

Patients with low AIF1L expression showed a poor disease-free survival rate (*P*=0.040; [Figure 1](#f1-ott-11-5485){ref-type="fig"}). The hazard ratio (HR) for AIF1L protein expression was 0.610 (95% CI, 0.377--0.987; *P*=0.044) in the AIF1L-positive group (univariate analysis). Seven baseline variables (age, T&N stage subtype, ER status, PR status, HER2 status, and Ki67 status) were evaluated with AIF1L expression using Cox regression analysis. The HR for AIF1L was not significantly changed (HR=0.724 \[95% CI, 0.404--1.298\]; *P*=0.278).

Potential biological functions of AIF1L
---------------------------------------

To explore the unique roles of AIF1L, we identified 196 AIF1L co-expression genes from the CCLE database with R language by setting the Pearson coefficient ⩾0.6. After performing gene ontology and the Kyoto Encyclopedia of Genes and Genomes pathway analysis using DAVID tools,[@b17-ott-11-5485] the most enriched biological themes were related to tight junctions and cell junctions ([Figure 2A](#f2-ott-11-5485){ref-type="fig"}). To further assess the biological function of AIF1L in breast tumorigenesis, we applied GSEA to BC cells from the CCLE. Top 50 differentially expressed genes between low vs high expressions of AIF1L are shown in [Table S1](#SD2-ott-11-5485){ref-type="supplementary-material"}. Downregulation of AIF1L was significantly correlated with focal adhesion (FA; [Figure 2B](#f2-ott-11-5485){ref-type="fig"}). Genes in the FA pathway were identified by GSEA ([Figure 2C](#f2-ott-11-5485){ref-type="fig"}; [Table S2](#SD3-ott-11-5485){ref-type="supplementary-material"}).

AIF1L inhibits migration and invasion of MDA-MB-231 BC cells
------------------------------------------------------------

The mRNA expression levels of BC cells in CCLE are shown [Figure S1](#SD1-ott-11-5485){ref-type="supplementary-material"}. AIF1L expression of MDA-MB-231 cells was lower than that of immortalized epithelial HMEL cells. To further investigate the effect of AIF1L overexpression on cell migration and invasion, the Transwell migration and invasion assays were performed. Transwell migration and invasion assays showed that transient overexpression of AIF1L significantly suppressed migration and invasion compared to the control group (*P*⩽0.05; [Figure 3](#f3-ott-11-5485){ref-type="fig"}).

AIF1L inhibits MDA-MB-231 cell spreading and mediates focal adhesion kinase (FAK) levels involved in ROCK signaling
-------------------------------------------------------------------------------------------------------------------

Cell migration and spreading are initiated by global reorganization of the actin cytoskeleton and extending actin polymerization-driven lamellipodium protrusions of the cell membrane.[@b29-ott-11-5485],[@b30-ott-11-5485] Thirty minutes after plating, cells overexpressing AIF1L spread less efficiently than the control cells ([Figure 4A, B, E](#f4-ott-11-5485){ref-type="fig"}) and were less elongated, as indicated by an increase in circularity and decrease in aspect ratio ([Figure 4C--F](#f4-ott-11-5485){ref-type="fig"}). Elongated cells showed actin remodeling toward the membrane, which is equivalent to the formation of ruffles and pseudopodia ([Figure 4D](#f4-ott-11-5485){ref-type="fig"}).

FAK is a nonreceptor tyrosine kinase that plays a central role in cell migration through regulation of lamellipodial formation and FAs.[@b31-ott-11-5485],[@b32-ott-11-5485] Increased FAK expression has been correlated with increased clinical progression in BC.[@b33-ott-11-5485],[@b34-ott-11-5485] Therefore, we assessed FAK expression in AIF1L-overexpressing MDA-MB-231 cells and controls and showed that AIF1L led to increased inhibition of FAK expression ([Figure 4G](#f4-ott-11-5485){ref-type="fig"}). FAK is involved with activators and/or inhibitors of the small GTPase RhoA that enable FAK activity to be connected to alterations in polymerization of actin filaments during tumor cell adhesion and motility.[@b35-ott-11-5485],[@b36-ott-11-5485] RhoA expression was also inhibited by AIF1L overexpresssion in MDA-MB-231 cells ([Figure 4G](#f4-ott-11-5485){ref-type="fig"}).

Discussion
==========

In the present study, we analyzed the expression and clinicopathologic significance of AIF1L in BC. Low AIF1L protein expression was observed in 71.4% of BC samples in this cohort. AIF1L mRNA expression was also lower in patients with BC in TCGA cohort. Furthermore, AIF1L protein expression in BC was confirmed from Protein Atlas. Thus, AIF1L expression is downregulated in BC. Furthermore, we integrated AIF1L DNA methylation and gene expression from TCGA database and found that AIF1L downregulation may be due to hypermethylation of the promoter. Given that the Spearman correlation coefficient was very low, particularly with tumor tissues, we searched[@b51-ott-11-5485] and found that no genetic alterations in AIF1L were reported in 977 sequenced patients from TCGA. We hypothesized that in addition to methylation, there might be some other reason for AIF1L downregulation, such as a posttranscriptional regulation mechanism rather than gene mutation. Low AIF1L expression was detected in TNBC and was correlated with a poor postoperative disease-specific survival. TNBC accounts for \~15%--20% of BCs and is defined by the absence of ERα, PR, and HER2 amplification, which is resistant to conventional chemotherapy, lack of targeting agents and is often associated with a poor prognosis.[@b37-ott-11-5485],[@b38-ott-11-5485] AIF1L could be a unique molecular target of TNBCs.

CCLE data analysis revealed AIF1L-related pathways, including cell junction, tight junction, and FA. Of the AIF1L co-expression genes, CDH1 (cadherin 1, E-cadherin) is a major component of intercellular junctions, and loss of its expression has been shown to reduce BC invasion and metastasis.[@b39-ott-11-5485],[@b40-ott-11-5485] FAs connect the cytoskeleton and extracellular matrix (ECM). Interplay between the actin cytoskeleton and FA dynamics results in a balance between adhesion and contraction, which greatly influences cell migration.[@b35-ott-11-5485],[@b41-ott-11-5485]

Although AIF1L induces cytoskeletal rearrangements in HeLa cells and podocytes, whether it is involved in BC progression, especially in TNBCs, is not understood. The data reported herein show that ectopic AIF1L expression suppresses MDA-MB-231 BC cell motility and invasion by inducing cytoskeletal modifications, which are achieved through FAK/RHOA signaling. High FAK expression was correlated with shorter overall survival and progression-free survival in patients with BC, especially in TNBC patients with high FAK expression.[@b42-ott-11-5485],[@b43-ott-11-5485] RhoA protein is also overexpressed in BC.[@b44-ott-11-5485],[@b45-ott-11-5485] The actin cytoskeleton is linked to invasive and metastatic phenotypes of malignant cancer cells. Cell migration is driven by cycles of actin polymerization and is initiated by cell membrane protrusions called filopodia, lamellipodia, and invadopodia.[@b46-ott-11-5485] These protrusions are stabilized by adhesions linking the actin cytoskeleton to ECM proteins and actomyosin contraction.[@b35-ott-11-5485],[@b47-ott-11-5485] Located on the inner face of the cell membrane, FAs form a vital link between the ECM and the cytoskeleton. Interplay between F-actin contractile forces and FA dynamics greatly influences cell migration capacity.[@b35-ott-11-5485] Integrin receptor binding to ECM proteins is one of the strongest activators of FAK.[@b48-ott-11-5485],[@b49-ott-11-5485] In the present study, MDA-MB-231 cells transfected with AIF1L showed decreased cell spreading, more circular cell shape, and formation of fewer protrusions. GSEA also found low AIF1L expression correlated with high expression of collagens such as COL4, COL6, COL5, and COL1. AIF1L may inhibit FAK/RHOA expression through interfering in cell--ECM signaling. But the accurate molecular mechanism needs further research. These results support a role for AIF1L in regulating actin remodeling associated with cell migration.

Conclusion
==========

This study evaluated AIF1L expression in BC and found that AIF1L downregulation may predict a poor prognosis. AIF1L suppresses BC migration and invasion through regulating actin remodeling, which is dependent on FAK/RHOA signaling. However, additional mechanisms that influence AIF1L regulation of the actin cytoskeleton should be identified and characterized in the future.

Supplementary materials
=======================

###### 

AIF1L expression levels in the breast cell of CCLE.

**Note:** Rectangle around MDA-MB-231 shows indicates AIF1L expression level was lower in MDA-MB-231 cell. **Abbreviation:** CCLE, Cancer Cell Line Encyclopedia.

###### 

Differentially expressed genes between low vs high expressions of AIF1L gene in CCLE breast cell database

  Name           Gene_symbol   Gene_title                                                                                      Score
  -------------- ------------- ----------------------------------------------------------------------------------------------- ----------
  FOSL1          *FOSL1*       FOS-like antigen 1                                                                              0.837046
  EMP3           *EMP3*        Epithelial membrane protein 3                                                                   0.802068
  ZDHHC2         *ZDHHC2*      Zinc finger, DHHC-type containing 2                                                             0.790615
  AXL            *AXL*         AXL receptor tyrosine kinase                                                                    0.781382
  IGFBP7         *IGFBP7*      Insulin-like growth factor binding protein 7                                                    0.76961
  SERPINE1       *SERPINE1*    Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   0.75092
  COL4A2         *COL4A2*      Collagen, type IV, alpha 2                                                                      0.746052
  TGFB1I1        *TGFB1I1*     Transforming growth factor beta 1 induced transcript 1                                          0.729768
  IGFBP6         *IGFBP6*      Insulin-like growth factor binding protein 6                                                    0.725726
  COL4A1         *COL4A1*      Collagen, type IV, alpha 1                                                                      0.707212
  HRH1           *HRH1*        Histamine receptor H1                                                                           0.690314
  BCAT1          *BCAT1*       Branched chain aminotransferase 1, cytosolic                                                    0.685178
  PROCR          *PROCR*       Protein C receptor, endothelial (EPCR)                                                          0.684549
  COL6A2         *COL6A2*      Collagen, type VI, alpha 2                                                                      0.667416
  PHLDA1         *PHLDA1*      Pleckstrin homology-like domain, family A, member 1                                             0.667399
  SLFN12         *SLFN12*      Schlafen family member 12                                                                       0.663343
  RAB34          *RAB34*       RAB34, member RAS oncogene family                                                               0.646708
  PLAU           *PLAU*        Plasminogen activator, urokinase                                                                0.640417
  AKAP12         *AKAP12*      A kinase (PRKA) anchor protein (gravin) 12                                                      0.630199
  DFNA5          *DFNA5*       Deafness, autosomal dominant 5                                                                  0.629837
  LHFP           *LHFP*        Lipoma HMGIC fusion partner                                                                     0.627571
  SPOCK1         *SPOCK1*      Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1                        0.622842
  FAM101B        *FAM101B*     Family with sequence similarity 101, member B                                                   0.619061
  COL6A1         *COL6A1*      Collagen, type VI, alpha 1                                                                      0.611874
  ADAM19         *ADAM19*      ADAM metallopeptidase domain 19 (meltrin beta)                                                  0.610056
  COL5A2         *COL5A2*      Collagen, type V, alpha 2                                                                       0.607276
  TIMP1          *TIMP1*       TIMP metallopeptidase inhibitor 1                                                               0.606783
  SCG2           *SCG2*        Secretogranin II (chromogranin C)                                                               0.60473
  NOV            *NOV*         Nephroblastoma overexpressed gene                                                               0.604233
  TMEM158        *TMEM158*     Transmembrane protein 158                                                                       0.603507
  DKK3           *DKK3*        Dickkopf homolog 3 (*Xenopus laevis*)                                                           0.602322
  PRR16          *PRR16*       Proline rich 16                                                                                 0.599183
  IL6            *IL6*         Interleukin 6 (interferon, beta 2)                                                              0.598937
  LIF            *LIF*         Leukemia inhibitory factor (cholinergic differentiation factor)                                 0.597241
  FGF2           *FGF2*        Fibroblast growth factor 2 (basic)                                                              0.596823
  TNFAIP3        *TNFAIP3*     Tumor necrosis factor, alpha-induced protein 3                                                  0.595126
  GLIS3          *GLIS3*       GLIS family zinc finger 3                                                                       0.594521
  EPHA2          *EPHA2*       EPH receptor A2                                                                                 0.593322
  NT5E           *NT5E*        5′-nucleotidase, ecto (CD73)                                                                    0.586506
  TMEM22         *TMEM22*      Transmembrane protein 22                                                                        0.586264
  FYN            *FYN*         FYN oncogene related to SRC, FGR, YES                                                           0.584119
  PTRF           *PTRF*        Polymerase I and transcript release factor                                                      0.583833
  MMP2           *MMP2*        Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase)         0.583674
  TMEM133        *TMEM133*     Transmembrane protein 133                                                                       0.582601
  PTPRM          *PTPRM*       Protein tyrosine phosphatase, receptor type, M                                                  0.580363
  IGF2BP3        *IGF2BP3*     Insulin-like growth factor 2 mRNA binding protein 3                                             0.57938
  FBN1           *FBN1*        Fibrillin 1                                                                                     0.576254
  CAV1           *CAV1*        Caveolin 1, caveolae protein, 22 kDa                                                            0.575581
  CDH2           *CDH2*        Cadherin 2, type 1, N-cadherin (neuronal)                                                       0.573586
  FSTL1          *FSTL1*       Follistatin-like 1                                                                              0.571101
  FGF13          *FGF13*       Fibroblast growth factor 13                                                                     −0.44624
  CYP4X1         *CYP4X1*      Cytochrome P450, family 4, subfamily X, polypeptide 1                                           −0.44881
  PRSS8          *PRSS8*       Protease, serine 8 (prostasin)                                                                  −0.44885
  HRASLS         *HRASLS*      HRAS-like suppressor                                                                            −0.4543
  CDH1           *CDH1*        Cadherin 1, type 1, E-cadherin (epithelial)                                                     −0.45663
  SYCP2          *SYCP2*       Synaptonemal complex protein 2                                                                  −0.45812
  ZNF138         *ZNF138*      Zinc finger protein 138                                                                         −0.45815
  REPS2          *REPS2*       RALBP1-associated Eps domain containing 2                                                       −0.46265
  C19orf46       *C19ORF46*    Chromosome 19 open reading frame 46                                                             −0.46353
  VTCN1          *VTCN1*       V-set domain containing T cell activation inhibitor 1                                           −0.46819
  C1orf172       *C1ORF172*    Chromosome 1 open reading frame 172                                                             −0.46911
  MAPT           *MAPT*        Microtubule-associated protein tau                                                              −0.47075
  IGSF9          *IGSF9*       Immunoglobulin superfamily, member 9                                                            −0.47255
  C9orf152       *C9ORF152*    Chromosome 9 open reading frame 152                                                             −0.47257
  RAB25          *RAB25*       RAB25, member RAS oncogene family                                                               −0.4732
  KIAA1324       *KIAA1324*    KIAA1324                                                                                        −0.4738
  FOXA1          *FOXA1*       Forkhead box A1                                                                                 −0.47381
  SPDEF          *SPDEF*       SAM pointed domain containing ets transcription factor                                          −0.47942
  REEP1          *REEP1*       Receptor accessory protein 1                                                                    −0.48044
  CGN            *CGN*         Cingulin                                                                                        −0.48205
  OAZ3           *OAZ3*        Ornithine decarboxylase antizyme 3                                                              −0.48362
  MB             *MB*          myoglobin                                                                                       −0.48515
  NEBL           *NEBL*        Nebulette                                                                                       −0.48792
  ST6GAL1        *ST6GAL1*     ST6 beta-galactosamide alpha-2,6-sialyltranferase 1                                             −0.49266
  ALDH3B2        *ALDH3B2*     Aldehyde dehydrogenase 3 family, member B2                                                      −0.49449
  CLDN4          *CLDN4*       Claudin 4                                                                                       −0.49664
  LOC100506497   *Null*        Null                                                                                            −0.50289
  GRHL2          *GRHL2*       Grainyhead-like 2 (*Drosophila*)                                                                −0.50291
  CLDN3          *CLDN3*       Claudin 3                                                                                       −0.50757
  ZNF467         *ZNF467*      Zinc finger protein 467                                                                         −0.50862
  SIDT1          *SIDT1*       SID1 transmembrane family, member 1                                                             −0.51057
  CEBPA          *CEBPA*       CCAAT/enhancer binding protein (C/EBP), alpha                                                   −0.51303
  BSPRY          *BSPRY*       B-box and SPRY domain containing                                                                −0.51612
  RASEF          *RASEF*       RAS and EF-hand domain containing                                                               −0.5214
  IRX5           *IRX5*        Iroquois homeobox protein 5                                                                     −0.52766
  EPN3           *EPN3*        Epsin 3                                                                                         −0.53665
  EFNA3          *EFNA3*       Ephrin-A3                                                                                       −0.54208
  SELENBP1       *SELENBP1*    Selenium binding protein 1                                                                      −0.54401
  GLYATL2        *GLYATL2*     Glycine-*N*-acyltransferase-like 2                                                              −0.54889
  GRHL1          *GRHL1*       Grainyhead-like 1 (*Drosophila*)                                                                −0.5533
  CRABP2         *CRABP2*      Cellular retinoic acid binding protein 2                                                        −0.55677
  HEY2           *HEY2*        Hairy/enhancer-of-split related with YRPW motif 2                                               −0.56036
  TFAP2C         *TFAP2C*      Transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)                   −0.5666
  RERG           *RERG*        RAS-like, estrogen-regulated, growth inhibitor                                                  −0.56686
  SYT12          *SYT12*       Synaptotagmin XII                                                                               −0.57878
  CYP4Z1         *CYP4Z1*      Cytochrome P450, family 4, subfamily Z, polypeptide 1                                           −0.61774
  EFHD1          *EFHD1*       EF-hand domain family, member D1                                                                −0.62168
  PRLR           *PRLR*        Prolactin receptor                                                                              −0.62633
  MYB            *MYB*         v-myb myeloblastosis viral oncogene homolog (avian)                                             −0.6605
  VAV3           *VAV3*        vav 3 oncogene                                                                                  −0.75064

**Abbreviation:** CCLE, Cancer Cell Line Encyclopedia.

###### 

The most affected genes in the HSA04510_FOCAL_ADHESION pathway

  Name     Gene_symbol   Gene_title                                                                          Rank in gene list   Rank metric score   Running es
  -------- ------------- ----------------------------------------------------------------------------------- ------------------- ------------------- ------------
  row_0    *COL4A2*      Collagen, type IV, alpha 2                                                          6                   0.746052            0.024102
  row_1    *COL4A1*      Collagen, type IV, alpha 1                                                          9                   0.707211            0.047146
  row_2    *COL6A2*      Collagen, type VI, alpha 2                                                          13                  0.667416            0.068834
  row_3    *COL6A1*      Collagen, type VI, alpha 1                                                          25                  0.611874            0.088276
  row_4    *COL5A2*      Collagen, type V, alpha 2                                                           27                  0.607276            0.108102
  row_5    *FYN*         FYN oncogene related to SRC, FGR, YES                                               45                  0.584118            0.126316
  row_6    *CAV1*        Caveolin 1, caveolae protein, 22 kDa                                                52                  0.575581            0.144838
  row_7    *VEGFC*       Vascular endothelial growth factor C                                                72                  0.553132            0.161931
  row_8    *COL1A2*      Collagen, type I, alpha 2                                                           81                  0.540925            0.179211
  row_9    *AKT3*        v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)             117                 0.493746            0.193506
  row_10   *ITGA4*       Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)                145                 0.472133            0.20752
  row_11   *FLNC*        Filamin C, gamma (actin binding protein 280)                                        200                 0.44223             0.219114
  row_12   *LAMC2*       Laminin, gamma 2                                                                    203                 0.441652            0.233465
  row_13   *CAV2*        Caveolin 2                                                                          215                 0.436721            0.247174
  row_14   *LAMA4*       Laminin, alpha 4                                                                    225                 0.433796            0.260894
  row_15   *BIRC3*       Baculoviral IAP repeat-containing 3                                                 226                 0.433145            0.275073
  row_16   *ITGA3*       Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)                235                 0.427453            0.288639
  row_17   *ITGA5*       Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)                         241                 0.425145            0.302289
  row_18   *COL3A1*      Collagen, type III, alpha 1 (Ehlers--Danlos syndrome type IV, autosomal dominant)   278                 0.406763            0.313683
  row_19   *ITGA6*       Integrin, alpha 6                                                                   282                 0.405993            0.326814
  row_20   *LAMB3*       Laminin, beta 3                                                                     287                 0.403633            0.339813
  row_21   *PDGFC*       Platelet-derived growth factor C                                                    299                 0.400535            0.352338
  row_22   *LAMC1*       Laminin, gamma 1 (formerly LAMB2)                                                   346                 0.382794            0.362413
  row_23   *FN1*         Fibronectin 1                                                                       360                 0.376867            0.374056
  row_24   *COL5A1*      Collagen, type V, alpha 1                                                           365                 0.375251            0.386127
  row_25   *MYL9*        Myosin, light chain 9, regulatory                                                   369                 0.373747            0.398201
  row_26   *MYLK*        Myosin, light chain kinase                                                          387                 0.368815            0.409367
  row_27   *PDGFA*       Platelet-derived growth factor alpha polypeptide                                    501                 0.33853             0.414418
  row_28   *PIK3CD*      Phosphoinositide-3-kinase, catalytic, delta polypeptide                             531                 0.329876            0.423668
  row_29   *LAMB1*       Laminin, beta 1                                                                     532                 0.329803            0.434465
  row_30   *PRKCA*       Protein kinase C, alpha                                                             533                 0.329702            0.445257
  row_31   *COL1A1*      Collagen, type I, alpha 1                                                           536                 0.329197            0.455927
  row_32   *ITGB4*       Integrin, beta 4                                                                    581                 0.321616            0.464107
  row_33   *LAMA2*       Laminin, alpha 2 (merosin, congenital muscular dystrophy)                           586                 0.320621            0.474389
  row_34   *COL6A3*      Collagen, type VI, alpha 3                                                          588                 0.32032             0.484821
  row_35   *MET*         met proto-oncogene (hepatocyte growth factor receptor)                              604                 0.316587            0.494384
  row_36   *THBS1*       Thrombospondin 1                                                                    698                 0.297631            0.499164
  row_37   *COL4A6*      Collagen, type IV, alpha 6                                                          749                 0.288689            0.505945
  row_38   *SPP1*        Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early                  782                 0.281494            0.513452
                         T-lymphocyte activation 1)                                                                                                  
  row_39   *LAMB2*       Laminin, beta 2 (laminin S)                                                         838                 0.268912            0.519319
  row_40   *PARVA*       Parvin, alpha                                                                       880                 0.259453            0.525624
  row_41   *PDGFRB*      Platelet-derived growth factor receptor, beta polypeptide                           915                 0.25332             0.532102
  row_42   *PGF*         Placental growth factor, vascular endothelial growth factor-related protein         998                 0.241213            0.535622
  row_43   *ACTN1*       Actinin, alpha 1                                                                    1,007               0.240274            0.54306
  row_44   *TNC*         Tenascin C (hexabrachion)                                                           1,012               0.239859            0.550698
  row_45   *FLNA*        Tilamin A, alpha (actin-binding protein 280)                                        1,066               0.23099             0.555431
  row_46   *RAC2*        ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding           1,087               0.227534            0.561812
                         protein Rac2)                                                                                                               
  row_47   *PARVB*       Parvin, beta                                                                        1,129               0.222995            0.566924
  row_48   *TLN1*        Talin 1                                                                             1,239               0.209093            0.567951
  row_49   *VCL*         Vinculin                                                                            1,253               0.2071              0.574036
  row_50   *ZYX*         Zyxin                                                                               1,275               0.204779            0.579619
  row_51   *COL5A3*      Collagen, type V, alpha 3                                                           1,409               0.19049             0.578756
  row_52   *PXN*         Paxillin                                                                            1,482               0.184277            0.580945
  row_53   *COL11A1*     Collagen, type XI, alpha 1                                                          1,517               0.180528            0.58504
  row_54   *CAPN2*       Calpain 2, (m/II) large subunit                                                     1,554               0.176329            0.588891
  row_55   *LAMA1*       Laminin, alpha 1                                                                    1,609               0.170144            0.591579
  row_56   *ACTN4*       Actinin, alpha 4                                                                    1,645               0.16764             0.595198
  row_57   *ITGAV*       Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)           1,728               0.160049            0.596061
  row_58   *PDGFRA*      Platelet-derived growth factor receptor, alpha polypeptide                          1,742               0.158875            0.600568
  row_59   *ITGA8*       Integrin, alpha 8                                                                   1,754               0.158028            0.605154
  row_60   *SHC3*        SHC (Src homology 2 domain containing) transforming protein 3                       1,763               0.157112            0.60987
  row_61   *ITGA11*      Integrin, alpha 11                                                                  1,768               0.15679             0.614789
  row_62   *SHC1*        SHC transforming protein 1                                                          1,818               0.153003            0.617182
  row_63   *THBS2*       Thrombospondin 2                                                                    1,826               0.152263            0.621793
  row_64   *CCND1*       Cyclin D1                                                                           1,879               0.149562            0.623914
  row_65   *ITGA2*       Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                        1,881               0.14919             0.628744
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###### 

AIF1L expression levels in 287 surgical tissue samples from breast cancer patients were assessed by immunohistochemistry.

**Notes:** (**A**) Positive AIF1L staining in surrounding non-tumor areas; (**B**) Negative AIF1L staining; (**C**) Positive AIF1L staining. (**D**) Low AIF1L expression is associated with poor survival in breast cancer patients, *P*=0.040. AIF1L expression levels from TCGA. (**E**) AIF1L methylation levels were higher in breast cancer cells compared to normal controls. (**F**) AIF1L mRNA expression was lower in breast cancer cells compared to normal controls, both *P*⩽0.05 (*P*-value were calculated by t-test). (**G**) Negative correlation between AIF1L methylation levels and mRNA expression, *r*=−0.371 in normal samples; *r*=−0.133 in breast cancer samples (spearman correlation coefficient).
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![Gene set enrichment analysis (GSEA) and DAVID functional annotation clustering using public repository data from CCLE.\
**Notes:** (**A**) DAVID functional annotation clustering for AIF1L co-expression genes. (**B**) GSEA for HSA04510_FOCAL_ADHESION, which is related to low AIF1L expression. (**C**) Genes in the HSA04510_FOCAL_ADHESION pathway are upregulated in breast cancer cells with low AIF1L levels.\
**Abbreviation:** FDR, false discovery rate.](ott-11-5485Fig2){#f2-ott-11-5485}

![Decreased migration and invasion of MDAMB-231 cells with transient AIF1L overexpression.\
**Notes:** Cell migration (**A**) and invasion (**C**) were detected using transwell assays. Representative images are shown following staining with crystal violet. Quantification of cell migration (**B**) and invasion (**D**) are also shown.](ott-11-5485Fig3){#f3-ott-11-5485}

![AIF1L inhibits cell spreading and alters cell morphology.\
**Notes:** (**A**, **B**) AIF1L overexpression in MDA-MB-231 cells resulted in slower spreading on a matrigel coated surface compared with controls. Representative images of cells stained using TRITC-phalloidin and DAPI to show the nuclei. (**C**, **D**) Example images of rounded cells and elongated cells. (**E**) Average area of cells ± SEM from a minimum of 50 cells for each treatment. (**F**) Cell circularity and aspect ratio were measured from at least 50 cells for AIF1L overexpression in MDA-MB-231 cells and controls. AIF1L increased circularity and reduced the aspect ratio on a matrigel coated surface compared with controls. Arrows show cell protrusions. Statistical significance was evaluated using the two-sample t-test: \**P*⩽0.05. (**G**) A representative Western blot demonstrating downregulation of FAK and RHOA expression in MDA-MB-231 cells overexpressing AIF1L.](ott-11-5485Fig4){#f4-ott-11-5485}

###### 

Clinicopathologic characteristics and AIF1L protein expression

  Characteristics                                          n     AIF1L-low   AIF1L-high (n, %)   *P*-value
  -------------------------------------------------------- ----- ----------- ------------------- ------------------------------------------------------------
  Age (years)                                                                                    0.056
   ≤45                                                     91    72          19 (20.9)           
   \>45                                                    195   133         62 (31.8)           
  T stage                                                                                        0.35
   T1                                                      97    65          32 (33.0)           
   T2                                                      135   101         34 (25.2)           
   T3                                                      6     5           1 (16.7)            
  N stage                                                                                        0.331
   N0                                                      174   130         44 (25.3)           
   NI                                                      61    38          23 (37.7)           
   N2                                                      27    19          8 (29.6)            
   N3                                                      17    12          5 (29.4)            
  ER status                                                                                      0.339
   Negative                                                74    56          18 (24.3)           
   Positive                                                202   141         61 (30.2)           
  PR status                                                                                      0.653
   Negative                                                78    57          21 (26.9)           
   Positive                                                199   140         59 (29.6)           
  HER2 status                                                                                    0.038
   Negative                                                246   181         65 (26.4)           
   Positive                                                21    11          10 (47.6)           
  Ki67 status                                                                                    0.503
   ≤14%                                                    201   144         57 (28.4)           
   \>14%                                                   31    24          7 (22.6)            
  Molecular subtype                                                                              
   Luminal A[\*](#tfn1-ott-11-5485){ref-type="table-fn"}   158   113         45 (28.5)           0.052 ([\*](#tfn1-ott-11-5485){ref-type="table-fn"} vs \$)
   Luminal B[\#](#tfn2-ott-11-5485){ref-type="table-fn"}   29    19          10 (34.5)           0.038 ([\#](#tfn2-ott-11-5485){ref-type="table-fn"} vs \$)
   TNBC[\$](#tfn3-ott-11-5485){ref-type="table-fn"}        38    33          5 (13.2)            
   HER2+[&](#tfn4-ott-11-5485){ref-type="table-fn"}        12    6           6 (50)              0.007 ([&](#tfn4-ott-11-5485){ref-type="table-fn"} vs \$)

**Notes:**

Luminal A;

Luminal B;

TNBC;

HER2+.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNBC, triple-negative breast cancer.
